Sirolimus topical

Drug Profile

Sirolimus topical

Alternative Names: TD201

Latest Information Update: 23 Mar 2017

Price : $50

At a glance

  • Originator TransDerm
  • Class Anti-infectives; Antifungals; Antineoplastics; Lactones; Macrolides; Polyenes; Pyridines
  • Mechanism of Action Immunosuppressants; MTORC1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Palmoplantar keratoderma

Most Recent Events

  • 23 Mar 2017 No recent reports of development identified - Phase-I/II for Palmoplantar keratoderma in USA (Topical)
  • 15 Mar 2016 Biomarkers information updated
  • 01 Nov 2015 TransDerm completes a phase I/II trial in Palmoplantar keratoderma in USA (NCT02152007)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top